Efaproxiral and Brain Metastases Treatment
Author Information
Author(s): Stea B, Shaw E, Pintér T, Hackman J, Craig M, May J, Steffen R P, Suh J H
Primary Institution: The University of Arizona Health Sciences Center
Hypothesis
Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
Conclusion
Patients with sufficient efaproxiral exposure experienced improved survival and response rates compared to those with lower exposure.
Supporting Evidence
- Patients achieving sufficient efaproxiral concentration were most likely to experience survival benefits.
- Breast cancer patients generally achieved the target efaproxiral exposure and gained greater benefit than NSCLC patients.
- The study defined the efaproxiral concentration-dependence in survival and response rate improvement.
Takeaway
This study found that giving a special drug called efaproxiral to patients with brain cancer can help them live longer and feel better if they get enough of it.
Methodology
Patients were randomized to receive whole-brain radiation therapy with or without efaproxiral, and their survival and response rates were analyzed based on efaproxiral exposure.
Potential Biases
Potential biases related to patient selection and treatment allocation.
Limitations
The study may not generalize to all types of brain metastases or to patients who did not meet the eligibility criteria.
Participant Demographics
Most patients were Caucasian (89%) and the mean age was 57 years, with a majority being female (56%).
Statistical Information
P-Value
P=0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website